Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to ...

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company ...

With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash following a series of setbacks for the biotech.

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management, as it targets up to 10% revenue ...

The new line of credit could ease pressure on the money-losing vaccine maker as it tries to chart its post-pandemic future.

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.